CMIC HLDGS CO LTD 2309

2309 TSE
2309
CMIC HLDGS CO LTD TSE
 
No trades
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E

2309 Chart

Trade 2309 with trusted brokers on TradingView Open account

Analyst rating

Valuation
Enterprise Value/EBITDA, TTM
Enterprise Value, FQ
Market Cap — Basic
Number of Employees
Number of Shareholders
Price/Earnings, TTM
Price/Revenue, TTM
Price/Book Ratio, FY
Price/Sales Ratio, FY
Balance Sheet
Current Ratio, FQ
Debt to Equity, FQ
Net Debt, FQ
Quick Ratio, FQ
Total Assets, FQ
Total Debt, FQ
Operating Metrics
Return on Assets, TTM
Return on Equity, TTM
Return on Invested Capital, TTM
Revenue per Employee, TTM
Price History
Average Volume (10 day)
Beta - 1 Year
Price - 52 Week High
Price - 52 Week Low
Dividends
Dividends Paid, FY
Dividends per Share, FY
Expected Annual Dividends
Dividends Yield
Margins
Net Margin, TTM
Gross Margin, TTM
Operating Margin, TTM
Pretax Margin, TTM
Income Statement
Basic EPS, Net Income
Earnings per Share, Basic, TTM
EBITDA, TTM
Gross Profit, FY
Last Annual EPS
Last Annual Revenue, FY
Net Income, FY
Total Revenue, FY
Free Cash Flow, TTM

Profile

Sector: Health Services
Industry: Medical/Nursing Services
CMIC Holdings Co., Ltd. engages in the provision of support services for pharmaceutical development, manufacturing, and sales. Its operations are carried out through the following segments: Contract Research Organization (CRO), Contract Manufacturing Organization (CMO), Contract Sales Organization (CSO), Health Care, and Intellectual Properties Development (IPD). The CRO segment provides the professional services related to the administration of clinical study and survey upon manufacture and sale such as monitoring, data management, pharmaceutical consulting, and preclinical businesses. The CMO segment handles the contract manufacture of medical supplies for pharmaceutical companies. The CSO segment includes sale and marketing support for pharmaceutical companies. The Health Care segment provides medical and support services for health maintenance and improvement. The IPD segment involves in the development and sale of diagnostic and orphan drugs. The company was founded by Kazuo Nakamura on March 14, 1985 and is headquartered in Tokyo, Japan.